Spyre says bowel disease drug cuts inflammation in mid-stage trial
- Posted on June 15, 2026
- By Bing News
- 0 Views
- 1 min read
Spyre says bowel disease drug cuts inflammation in mid-stage trial
June 15 (Reuters) - Spyre Therapeutics said on Monday its experimental bowel disease drug met the main goal of significantly reducing disease severity in a mid-stage trial. Here are some details: • The company is testing the drug, SPY002, in patients with moderate-to-severe ulcerative colitis that causes long-lasting ulcers and inflammation in the digestive tract. • The drug significantly
